Advanced imaging technologies capable of capturing deeper retinal structures were among the innovations highlighted by Device Technologies at RANZCO NZ 2026.
The company said its Topcon Triton2 swept-source OCT platform enables clinicians to image deeper ocular structures, particularly the choroid beneath the retina, which is increasingly recognised as an important site for detecting early pathological change.
Unlike conventional OCT systems, swept-source technology penetrates further into the eye with its 1,050nm wavelength, allowing clinicians to visualise structures that may provide earlier indicators of diseases such as age-related macular degeneration, said Device Technologies ophthalmic product specialist Regan Clark.
The Triton2 also incorporates widefield OCT angiography covering up to 21mm, utilising Topcon’s new Smart Denoise AI algorithm that enables retinal and choroidal blood flow to be assessed without the need for fluorescein dye injections.
"This may reduce the need for invasive fluorescein angiography in some patients while improving comfort and streamlining clinical workflows," he said.
